tbuckley/cabot-search huggingface dataset:
Neratinib in ERBB2-Positive Brain Metastases
Authors: Mark D. Pegram
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Delayed awakening after cardiac arrest: prevalence and risk factors in the Parisian registry
Authors: Marine Paul, Wulfran Bougouin, Guillaume Geri, Florence Dumas, Benoit Champigneulle, Stéphane Legriel, Julien Charpentier, Jean-Paul Mira, Claudio Sandroni, Alain Cariou
Journal: Intensive Care Medicine (2016)
76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC)
Authors: N. Karachaliou, I. Chaib, S. Pilotto, J. Codony, X. Cai, X. Li, S. Marin, C. Zhou, P. Cao, R. Rosell
Journal: Journal of Thoracic Oncology (2016)
BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.
Authors: Angelo Di Leo, Eva Ciruelos, Wolfgang Janni, Per Eystein Lonning, Ruth O'Regan, Michael Hubalek, Tibor Csoszi, Thomas Decker, Vivianne C. Tjan-Heijnen, Denis Weber, Mona El-Hashimy, Sasikiran Goteti, Cristian Massacesi, Thomas Denis Bachelot
Journal: Journal of Clinical Oncology (2015)

TPS626 Background: PI3K pathway activation is the most frequent alteration in BC and confers resistance to endocrine and mTORi treatment. The oral pan-PI3K inhibitor buparlisib has shown preliminary activity and a manageable safety profile in patients with HR+/HER2– BC in combination with letrozole or fulvestrant. Buparlisib + fulvestrant exhibits antitumor activity in mTORi-resistant ER+ xenograft models, suggesting that buparlisib may potentially bypass mTORi resistance by blocking upstream PI3K pathway signaling. Methods: BELLE-3 (NCT01633060) is a randomized, double-blind, placebo-controlled, Phase III study of fulvestrant ± buparlisib in postmenopausal women with HR+/HER2– locally advanced/metastatic BC. Key inclusion criteria: prior treatment with AIs, disease progression on or within 30 days of endocrine + mTORi therapy given as the last therapy before study entry, and ≤ 1 prior chemotherapy regimen for advanced disease. Approximately 420 women will be randomized (2:1) to receive buparlisib (100 mg...
NIMG-32MOLECULAR IMAGING AND IMMUNOHISTOCHEMICAL STUDIES OF THE KYNURENINE PATHWAY IN PATIENT-DERIVED XENOGRAFT MODELS OF GLIOBLASTOMA
Authors: Anthony Guastella, Neil Klinger, Lisa Polin, Csaba Juhász, Sharon Michelhaugh, Sandeep Mittal
Journal: Neuro-Oncology (2015)

BACKGROUND: Recently the kynurenine pathway (KP), which is responsible for ∼99% of the catabolism of the amino acid tryptophan (TRP), has been implicated in the pathophysiology of human gliomas. Furthermore, studies indicate that the KP plays a role in local anti-tumor immune suppression both directly and indirectly by depleting TRP and causing T-cell cell cycle arrest. The KP can be studied through the use of a non-invasive molecular imaging tracer, α-[11C]-methyl-L-tryptophan (AMT). AMT-PET can predict survival in GBM patients with recurrent disease (Kamson et al., Neuro-Oncology, 2014). METHODS: In order to study the KP, we generated patient-derived xenograft (PDX) models of five GBMs. One cell line, KCI-GBM-1040, was implanted intracranially and AMT scans were obtained 9 and 14 days post-op. In vivo analysis of the tumors was performed via immunohistochemistry (IHC) and AMT-PET scans. Formalin fixed tissue sections were stained with antibodies specific for human indoleamine 2,3-dioxygenase (IDO) 1, IDO2, tryptophan 2,3-dioxygenase (TDO2), kynureninase (KYNU), kynurenine 3-monooxygenase (KMO), and the large amino acid transporter, LAT1, which is responsible for the uptake of TRP and AMT. RESULTS: Micro-PET imaging showed robust tumoral AMT uptake in PDX mice with prolonged tracer accumulation over a 60-min scan, with average uptake increasing 38% between 10 minutes and the maximum at 50 minutes. This is consistent with AMT trapping seen in human gliomas. Tumor tissues from both the patient and xenografts showed similar immunostaining results for both the TRP-converting and the downstream enzymes of the KP. CONCLUSIONS: These preliminary results indicate that our PDX model is representative of the human disease as it relates to both the in vitro and in vivo study of the KP. These models allow us to study the KP and offer a novel system through which we can develop and test new therapies for GBM patients.
Interpretation of Clinical Trials That Stopped Early
Authors: Kert Viele, Anna McGlothlin, Kristine Broglio
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Co-Activation of Hedgehog and Met Pathways in Mediating Resistance to Gefitinib in Non-Small Cell Lung Cancer Cell Line Harboring Activating Mutation of Egfr
Authors: F. Morgillo, C.M. Della Corte, D. Vitagliano, M. Fasano, T. Troiani, E. Martinelli, F. Ciardiello
Journal: Annals of Oncology (2014)
Weightlessness: A Matter of Gravity
Authors: Nello Pace
Journal: New England Journal of Medicine (1977)

The advent of space flight has permitted man to leave his accustomed place on the surface of the earth and take the first tentative steps outward into the vastness of the universe. In doing so, man has also been able to remove himself for the first time from the influence of a major component of his physical environment, the constant and pervasive force of gravity. Although some of the physiologic consequences of such a radical departure from normal were predictable, many were not. Furthermore, it is not yet clear what all of them may be.One of the fundamental phenomena . . .
Principles and practice of conjoint psychoanalytic treatment
Authors: L R Ormont
Journal: American Journal of Psychiatry (1981)

The authors describes the advantages of conjoint analytic treatment, which occurs when two or more analysts treat a patient in different settings: one provides the one-to-one relationship, and the other leads the group experience. The goal of this treatment is to increase the therapeutic possibilities for the patient. The advantages come from the use of multiple settings, transferences, observers, interpreters, and maturational agents. The author illustrates the advantages of the treatment with several case reports. He also points out the value of conjoint treatment for the analysts involved.
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Authors: Luis Paz-Ares, Leora Horn, Hossein Borghaei, David R. Spigel, Martin Steins, Neal Ready, Laura Quan Man Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlesi, Martin Kohlhaeufl, Oscar Rodriguez, Marco Angelo Burgio, Jerome Fayette, Scott N. Gettinger, Christopher Harbison, Cécile Dorange, Friedrich Graf Finckenstein, Julie R. Brahmer
Journal: Journal of Clinical Oncology (2015)

LBA109 Background: Options for advanced non-SQ NSCLC patients (pts) who progress after platinum-based doublet chemotherapy (PT-DC) are limited, with minimal improvement in overall survival (OS). We report results from a randomized, global phase III study of NIVO, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC and tyrosine kinase inhibitor, if eligible. Methods: Pts were randomized to NIVO 3 mg/kg Q2W (n=292) or DOC 75 mg/m2 Q3W (n=290) until progression or discontinuation due to toxicity/other reasons. Primary objective was OS; Secondary objectives were investigator-assessed objective response rate (ORR; per RECIST v1.1), progression-free survival (PFS), efficacy by PD-L1 expression, quality of life, and safety. Results: NIVO demonstrated superior OS (HR=0.73; 96% CI: 0.59, 0.89; P=0.00155) and improved ORR (19.2% vs 12.4%; P=0.0235). HR for PFS was 0.92 (95% CI: 0.77, 1.11; P=0.393). PD-L1 expression was associated with benefit from NIVO (Table). In PD-L1+ pts, NIVO showed improved efficacy across all endpoints at predefined 1%, 5%, and 10% cut- points. Grade 3–5 drug-related AEs occurred in 10.5% (30/287) of NIVO and 53.7% (144/268) of DOC pts. No deaths were related to NIVO vs 1 DOC-related death. After discontinuation, 42.1% of NIVO and 49.7% of DOC pts received subsequent systemic therapy. Conclusions: NIVO demonstrated superior OS vs DOC in pts with advanced non-SQ NSCLC after failure of PT-DC. The safety profile of NIVO 3 mg/kg Q2W was favorable vs DOC. NIVO demonstrated survival benefit across histologies in two randomized phase III trials. Clinical trial information: NCT01673867. [Table: see text]
Case 3-2008
Authors: Ervin H. Epstein, Jo-Anne O. Shepard, Thomas J. Flotte
Journal: New England Journal of Medicine (2008)

An 80-year-old woman was seen in the dermatology clinic because of painful ulcerated lesions of the scalp. Basal-cell carcinomas had first developed on her back at 34 years of age and had spread to involve much of her body, particularly the scalp. Multiple excisions and grafts had been performed, but lesions recurred.
Interpretation of study's results is open to criticism
Authors: R. Bender, P. T Sawicki
Journal: BMJ (1996)

EDITOR,—The Microalbuminuria Collaborative Study Group concludes that intensive insulin treatment had no impact on the progression of nephropathy in insulin dependent diabetic patients with microalbuminuria.1 The analysis, presentation, and interpretation of their data, however, are open to criticism.

The main conclusion is based on a non-significant difference in the slopes of albumin excretion between the two groups. However, only the P value and a confidence interval for the overall mean slope are given, without descriptive information. The authors do not give the mean slopes for each group, standard …
A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer
Authors: H. Riess, A. Helm, M. Niedergethmann, I. Schmidt-Wolf, M. Moik, C. Hammer, K. Zippel, K. Weigang-Köhler, M. Stauch, H. Oettle
Journal: Journal of Clinical Oncology (2005)

LBA4009 Background: The combination of gemcitabine 1 g/m2 and 5-FU 750 mg/m2 as a continuous 24 h-infusion, modulated by folinic acid 200 mg/m2 given on d1, 8, 15, 22 every six weeks (GFF) showed interesting results in a multicenter phase II study (Oettle, Ann Oncol 2000). It was thus further explored in a phase III randomised study comparing it to gemcitabine standard therapy (G) (1 g/m2 weekly 7q8w, followed by 3q4w). Methods: Patients were randomised to receive GFF or G after stratification for disease extend and Karnofsky performance status (KPS). Eligibility criteria included KPS>= 60%, locally advanced or metastatic disease, no prior chemotherapy. Primary endpoint was median overall survival (mOS). Study was powered to detect a significant difference with 80% probability at a significance level of 0,05 when 392 death were observed. Secondary end-points include time to progression (TTP) and toxicity. Results: 473 pts. were randomised between 08/00 and 11/03. 235 pts. were allocated to GFF and 238 to G. Final analysis is scheduled for january 2005. Data on mOS, 1-year survival, TTP and toxicity will be presented. Statistics using Kaplan-Meier estimates and log-rank test for significance will be used for mOS and TTP. Conclusions: Will be reached after analysing the results. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Oncology Lilly Oncology
P239 Low prevalence of extra-thoracic airway hyper-responsiveness in UK patients with chronic refractory cough
Authors: A Menon, J Hull, KF Chung, O Usmani, S Ward
Journal: Thorax (2015)

<h3>Introduction</h3> Prior research indicates that chronic refractory cough (CRC) is associated with a high prevalence of extra-thoracic airway hyper-responsiveness (EAHR).<sup>1</sup> This heightened laryngoconstrictor reflex can be characterised using standard bronchoprovocation tests (e.g. histamine or hypertonic saline); whereby attenuation in the inspiratory component of the flow-volume curve is evaluated in response to escalating doses of the stimulus. <h3>Aims and objectives</h3> To determine the prevalence of EAHR in a cohort of CRC patients in the UK undergoing cough assessment, and to relate EAHR to other disease characteristics. <h3>Methods</h3> Data was retrospectively evaluated for all CRC patients completing cough assessment with histamine bronchoprovocation challenge, between 2013 and 2015. EAHR was defined by a 25% dose-responsive fall in the mid-inspiratory flow (PC25FIF50) in response to ≤ 8 mg/ml histamine.<sup>2</sup> EAHR data was compared with other simultaneous investigation results, including overnight pH/impedance results and co-existing nasal disease. <h3>Results</h3> We studied 57 adult CRC patients (n = 42, female; 74%), mean ±SD age 54.6 ± 12.4 years, BMI 28.2 ± 5.9 kg/m<sup>2</sup>, reporting a duration of cough 5.5 years (0.8–50) with a median cough VAS score of 57 (16–90). The majority of patients (56%) reported cough without other respiratory symptoms, whereas 12 (21%) reported cough with dyspnoea and wheeze. Evidence of EAHR was found in three patients (5.3%). At a reduced cut-off (PC20FIF50 ≤ 16 mg/ml) the prevalence of EAHR was greater (12%) (Figure 1). Patients with a positive EAHR test at this cut-off were younger (p &lt; 0.01, mean age 44 yrs versus 56 yrs) and more likely to report respiratory dyspnoea and wheeze (p &lt; 0.05). In patients completing an overnight reflux study (n = 52), 32 (62%) had evidence of reflux. 21 (37%) patients had co-existing nasal disease. However, presence of reflux or nasal disease was not predictive of EAHR (both p &gt; 0.05). <h3>Conclusion</h3> EAHR was not prevalent in CRC patients, completing assessment at a specialist cough service, when using a standard histamine bronchoprovocation test. Differences from prior published data may be explained by methodological differences, specifically the application of stringent control of the measures of reproducibility of inspiratory flow parameters and dose response criteria. <h3>References</h3> 1 Bucca C, Rolla G, Scappaticci E, <i>et al</i>. Histamine hyperresponsiveness of the extrathoracic airway in patients with asthmatic symptoms. <i>Allergy</i> 1991;<b>46</b>:147–53 2 Bucca C, Bugiani M, Culla B, <i>et al</i>. Chronic cough and irritable larynx. <i>J Allergy Clin Immunol</i>. 2011;<b>127</b>:412–9
Prevalence and Importance of Pigmented Ocular Fundus Lesions in Gardner's Syndrome
Authors: Elias I. Traboulsi, Anne J. Krush, Eldon J. Gardner, Susan V. Booker, G. Johan A. Offerhaus, John H. Yardley, Stanley R. Hamilton, Gordon D. Luk, Francis M. Giardiello, Steven B. Welsh, J. Preston Hughes, Irene H. Maumenee
Journal: New England Journal of Medicine (1987)

We examined 134 members of 16 families with Gardner's syndrome for pigmented ocular fundus lesions. Of 41 patients with documented Gardner's syndrome, 37 (90.2 percent) had such lesions. The lesions were bilateral in 32 of the patients (78.1 percent) and in 2 of 42 controls (4.8 percent). Twenty (46.5 percent) of 43 first-degree relatives at 50 percent risk for Gardner's syndrome had bilateral pigmented fundus lesions, indicating that they had probably inherited the abnormal gene. The presence of bilateral lesions, multiple lesions (more than four), or both appeared to be a specific (specificity, 0.952) and sensitive (sensitivity, 0.780) clinical marker for Gardner's syndrome. The lesions are probably congenital; they were observed in a three-month-old baby at risk. The multiplicity of the pigmented fundus lesions and their association with diffuse disturbances of the retinal pigment epithelium in the same eye suggest a widespread expression of the abnormal gene in the retinal pigment epithelial cells.
The Murmur of Peripheral Arteriovenous Fistula
Authors: Edward A. Edwards, Harold D. Levine
Journal: New England Journal of Medicine (1952)

THE detection of a continuous murmur with systolic accentuation is of the highest significance in the diagnosis and in the location of the site of an arteriovenous fistula. It is therefore appropriate to emphasize certain characteristics of the murmur that may increase its usefulness as a physical sign. The study of patients with arteriovenous fistula by auscultation has been supplemented by visual registration of the murmurs through the use of a microphone connected to the phonocardiographic channel of a multiple-channel electrocardiograph. Several phonoangiograms thus obtained are reproduced in this report. Simultaneous tracings of the pulse wave or the electrocardiogram are . . .
Hypoglycemia and Hyperinsulinism in Infants with Erythroblastosis Fetalis
Authors: Cynthia T. Barrett, Thomas K. Oliver
Journal: New England Journal of Medicine (1968)

Hypoglycemia was observed in five of 16 (31 per cent) consecutively studied infants with moderate to severe erythroblastosis fetalis. Hyperinsulinemia was documented in each of four infants on whom measurements were made. All infants with erythroblastosis fetalis should have measurements of blood glucose levels in the first hours of life and after exchange transfusion. If hypoglycemia develops in an infant with erythroblastosis fetalis he should be treated with glucose given intravenously.
Osteoporosis, Intestinal Lactase Deficiency and Low Dietary Calcium Intake
Authors: Stanley J. Birge, Henry T. Keutmann, Pedro Cuatrecasas, G. D. Whedon
Journal: New England Journal of Medicine (1967)

OSTEOPOROSIS (senile and postmenopausal) is a common disorder of the elderly, with an estimated morbidity of at least 20 per cent of persons over the age of fifty years.1 2 3 Despite this high prevalence, knowledge of the disorder remains unsatisfactory. There has been increasing acceptance of the concept that the demineralization of osteoporosis is the end result of a variety of metabolic influences acting either singly or in combination on the bony skeleton. It has previously been proposed3 4 5 6 that one cause or important contributing factor in osteoporosis is a dietary deficiency of calcium. Since milk constitutes the primary source of calcium . . .
Choosing Wisely Recommendations Using Administrative Claims Data
Authors: Daniel B. Wolfson
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Monitoring influenza activity in Europe with Google Flu Trends: comparison with the findings of sentinel physician networks – results for 2009-10
Authors: A Valdivia, J López-Alcalde, M Vicente, M Pichiule, M Ruiz, M Ordobas
Journal: Eurosurveillance (2010)

The number of Internet searches has recently been used by Google to estimate the influenza incidence in the United States. We examined the correlation between the Google Flu Trends tool and sentinel networks estimates in several European countries during the 2009 influenza A(H1N1) pandemic and found a good correlation between estimates and peak incidence timing, with the highest peaks in countries where Internet is most frequently used for health-related searching. Although somehow limited, Google could be a valuable tool for syndromic surveillance.
Case 32-2003
Authors: Annekathryn Goodman, David C. Wilbur
Journal: New England Journal of Medicine (2003)

Presentation of CaseA 37-year-old woman was referred to the colposcopy clinic because of two Papanicolaou smears showing atypical squamous cells of undetermined significance (ASC-US).One and two years previously, the patient had had Papanicolaou smears that were reported to be normal. Six months before referral, a routine pelvic examination revealed no abnormalities. A Papanicolaou smear at that time was interpreted as revealing ASC-US. The patient was reexamined three months later, and another Papanicolaou smear was again interpreted as showing ASC-US.The patient (gravida 5, para 4) had had one spontaneous first-trimester abortion. She was a native of El Salvador . . .